Recovery and assessment timescales in primary immunodeficiency extend from weeks to months. Initial post-infusion inflammatory responses subside within 1–2 weeks. Meaningful immune reconstitution — increased T-cell counts, restored T-cell proliferation — usually requires 4–12 weeks to manifest, reflecting lymphoid tissue regeneration timescales. T-cell subset enumeration, T-cell proliferation assays, and immunoglobulin levels are typically assessed at baseline, 4 weeks, 8 weeks, 12 weeks, 6 months, and 12 months post-infusion. Vaccine responses are re-assessed at 3–6 months post-infusion to measure functional antibody recovery. Infection monitoring continues throughout recovery; prophylactic antimicrobial therapy is typically maintained during early immune reconstitution. Patients should expect gradual immune improvement over months rather than acute recovery.
Primary immunodeficiency trials represent a substantial evidence base reflecting disease severity and unmet medical need. Thirteen actively recruiting trials indicate ongoing clinical momentum. Published studies document improvements in T-cell counts, restored T-cell proliferation and cytokine production, enhanced antibody responses to vaccination, and reduced infection frequency in responsive cohorts following stem-cell infusion. Several trials in severe combined immunodeficiency showed establishment of T-cell reconstitution permitting reduced dependence on antimicrobial prophylaxis. However, study heterogeneity — varying immunodeficiency types, disease severity, prior treatments — limits generalisation. Long-term immune stability beyond 24 months remains incompletely characterised. Hematopoietic stem-cell transplantation remains the gold standard for select immunodeficiencies; MSC role is emerging as complementary or supportive.
Sunt un candidat? → · Primary Immunodeficiency: full overview → · Cost Imunodefiență Primară → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită